Maayan Konigstein¹, MD; Nathalie Meyten², MD; Stefan Verheye², MD; Marc Schwartz3, RCIS; Shmuel Banai¹*, MD
1. Department of Cardiology, Tel Aviv Medical Center, Tel Aviv, Israel, and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 2. Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium; 3. Neovasc, Inc., Richmond, BC, Canada
Aims: To evaluate the clinical efficacy of the coronary sinus (CS) Reducer in attenuating angina severity in patients suffering from severe refractory angina.